Terms: = Colorectal cancer AND PRRX1, ENSG00000116132, 5396 AND Treatment
4 results:
1. A
Nygaard V; Ree AH; Dagenborg VJ; Børresen-Dale AL; Edwin B; Fretland ÅA; Grzyb K; Haugen MH; Mælandsmo GM; Flatmark K
Cancer Res Commun; 2023 Feb; 3(2):235-244. PubMed ID: 36968142
[TBL] [Abstract] [Full Text] [Related]
2. SPOCK1 silencing decreases 5-FU resistance through prrx1 in colorectal cancer.
Qu YL; Liu XL; Zhao SY; Zhai XF
Pathol Res Pract; 2022 Jun; 234():153895. PubMed ID: 35462225
[TBL] [Abstract] [Full Text] [Related]
3. MiR-124 Radiosensitizes human colorectal cancer cells by targeting prrx1.
Zhang Y; Zheng L; Huang J; Gao F; Lin X; He L; Li D; Li Z; Ding Y; Chen L
PLoS One; 2014; 9(4):e93917. PubMed ID: 24705396
[TBL] [Abstract] [Full Text] [Related]
4. [Analgesic effect of transcutaneous cranial electrostimulation in patients treated by Nd:YAG laser for cancer of the rectum. A double-blind randomized trial].
Naveau S; Barritault L; Zourabichvili O; Champagne C; Prieur G; Limoge A; Poynard T; Chaput JC
Gastroenterol Clin Biol; 1992; 16(1):8-11. PubMed ID: 1537485
[TBL] [Abstract] [Full Text] [Related]
